A study to assess efficacy of RXC004 ± nivolumab in ring finger protein 43 (RNF43) or R-spondin (RSPO) aberrated, metastatic, microsatellite stable, colorectal cancer after progression on the standard of care (SOC)73. This evidence concerns the gene RNF43 and colorectal cancer.